Home › Companies › TTRX

Turn Therapeutics

TTRX Lead: Phase 3 6 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-31

Pipeline (4 active programs)

GX-03

Small Molecule Target: IL-31, IL-36α, IL-36γ, IL-4, IL-36α/γ, IL-36

Moderate-to-Severe Eczema Phase 2 topical
Onychomycosis Phase 3 topical
Atopic Dermatitis Phase 2 topical

intranasal influenza vaccine

Influenza nasal

Technology platforms

PermaFusion · Medline

PermaFusion is an oil-based suspension delivery platform enabling uniform delivery of water-soluble actives without emulsifiers; applications include thermostable intranasal live vaccine stabilization and dermatologic/antifungal product formulations. Focus areas include vaccines and dermatology.

PermaFusion

Multi-patented, API-agnostic topical drug delivery platform enabling stable, emulsifier-free dispersion of active ingredients in oil-based carriers; delivers APIs through skin, nails, and mucous membranes via suspended nanodroplets in petrolatum matrix; compatible with liquid or liquid-soluble APIs including live payloads; focus on dermatological and inflammatory diseases

Biotech Distilled coverage (6)

2026-07-07 UPDATE: Turn Therapeutics (TTRX) - The Vehicle-Response Problem Just Got a Prospective Fix
2026-06-02 UPDATE: Turn Therapeutics (TTRX) - The Interim Drops, and the Vehicle Arm Did Not Get the Memo 🔒 Paid
2026-05-18 UPDATE: Turn Therapeutics (TTRX) - A Former FDA Commissioner Walks Into a Pre-Readout Small-Cap 🔒 Paid
2026-05-12 UPDATE: Turn Therapeutics (TTRX) - The Interim Clock Just Moved Up 🔒 Paid
2026-03-28 UPDATE: Turn Therapeutics (TTRX) - TTRX Buys Time with a $25M Lifeline... 🔒 Paid
2026-03-19 Turn Therapeutics (TTRX) - Scientific Deep Dive for GX-03 and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.